Focus on long non-coding RNA MALAT1: Insights into acute and chronic lung diseases

Xingning Lai; Jie Zhong; Aihua Zhang; Boyi Zhang; Tao Zhu; Ren Liao

doi:10.3389/fgene.2022.1003964

Focus on long non-coding RNA MALAT1: Insights into acute and chronic lung diseases

Front Genet. 2022 Sep 16:13:1003964. doi: 10.3389/fgene.2022.1003964. eCollection 2022.

Authors

Xingning Lai^{1

2}, Jie Zhong^{1

2}, Aihua Zhang^{1

2}, Boyi Zhang^{1

2}, Tao Zhu^{1

2}, Ren Liao^{1

2}

Affiliations

¹ Department of Anesthesiology, West China Hospital, Sichuan University, Chengdou, Sichuan, China.
² Research Unit for Perioperative Stress Assessment and Clinical Decision, Chinese Academy of Medical Sciences (2018RU012), West China Hospital, Sichuan University, Chengdou, Sichuan, China.

Abstract

Acute lung injury (ALI) is a pulmonary illness with a high burden of morbidity and mortality around the world. Chronic lung diseases also represent life-threatening situations. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a type of long non-coding RNA (lncRNA) and is highly abundant in lung tissues. MALAT1 can function as a competitive endogenous RNA (ceRNA) to impair the microRNA (miRNA) inhibition on targeted messenger RNAs (mRNAs). In this review, we summarized that MALAT1 mainly participates in pulmonary cell biology and lung inflammation. Therefore, MALAT1 can positively or negatively regulate ALI and chronic lung diseases (e.g., chronic obstructive pulmonary disease (COPD), bronchopulmonary dysplasia (BPD), pulmonary fibrosis, asthma, and pulmonary hypertension (PH)). Besides, we also found a MALAT1-miRNA-mRNA ceRNA regulatory network in acute and chronic lung diseases. Through this review, we hope to cast light on the regulatory mechanisms of MALAT1 in ALI and chronic lung disease and provide a promising approach for lung disease treatment.

Keywords: MALAT1; acute lung injury; chronic lung disease; inflammation; miRNA.

Publication types

Review